Original Articles
11 September 2025
Vol. 19 No. 3 (2025)
Exploring some pro-inflammatory cytokines and adipokines as novel biomarkers in polycystic ovary syndrome
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
223
Views
175
Downloads
4
HTML
Authors
Non-communicable diseases are more likely to affect women with polycystic ovarian syndrome (PCOS), in particular, mostly ascribed to the existence of low-grade chronic inflammation brought on by adipokines and proinflammatory cytokines. Angiopoietin-2, lipocalin-2, adipsin, and interleukin (IL)-22 concentrations in women with PCOS were assessed in this study, and their levels were compared to those in a healthy control group. Blood samples were obtained from outpatient and private gynecological clinics, as well as primary healthcare settings, from 55 women diagnosed with PCOS and 35 healthy control women. The serum concentrations of proinflammatory cytokines and adipokines were evaluated using the enzyme-linked immunosorbent assay technique. The data revealed that serum concentrations of angiopoietin-2, lipocalin-2, adipsin, and IL-22 were markedly increased in the PCOS cohort relative to the control cohort. Lipocalin-2 revealed a substantial positive correlation with adipsin, angiopoietin-2, and IL-22; likewise, angiopoietin-2 revealed a large positive correlation with adipsin and IL-22. Receiver operating characteristic curve analysis indicated that both lipocalin-2 and adipsin exhibited enhanced diagnostic efficacy for PCOS [area under the curve (AUC)=0.8518; AUC=0.8103, respectively], while angiopoietin-2 and IL-22 demonstrated moderate diagnostic significance for PCOS (AUC=0.7476; AUC=0.7340, respectively). Proinflammatory cytokines and adipokines showed significant diagnostic potential for identifying PCOS and may serve as markers for screening, thereby enhancing diagnostic accuracy for PCOS. These results suggest that lipocalin-2, adipsin, angiopoietin-2, and IL-22 could be utilized as biomarkers for assessing the risk of PCOS.
Altmetrics
Downloads
Download data is not yet available.
Citations
Bhattacharya K, Sengupta P, Dutta S, et al. Waist-to-height ratio and BMI as predictive markers for insulin resistance in women with PCOS in Kolkata, India. Endocrine 2021;72:86-95. DOI: https://doi.org/10.1007/s12020-020-02555-3
Bhattacharya K, Saha I, Sen D, et al. Role of anti-Mullerian hormone in polycystic ovary syndrome. Middle East Fertil Soc J. 2022;27:32. DOI: https://doi.org/10.1186/s43043-022-00123-5
Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88. DOI: https://doi.org/10.1016/j.fertnstert.2008.06.035
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018;14:270-84. DOI: https://doi.org/10.1038/nrendo.2018.24
Wu H, Yu K, Yang Z. Associations between TNF-α and interleukin gene polymorphisms with polycystic ovary syndrome risk: a systematic review and meta-analysis. J Assist Reprod Genet 2015;32:625-34. DOI: https://doi.org/10.1007/s10815-015-0449-7
Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008;14:222-31. DOI: https://doi.org/10.2119/2007-00119.Tilg
Chait A, Den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med 2020;7:522637. DOI: https://doi.org/10.3389/fcvm.2020.00022
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415-45. DOI: https://doi.org/10.1146/annurev-immunol-031210-101322
Lecke SB, Morsch D, Spritzer PM. Circulating levels and subcutaneous adipose tissue gene expression of pigment epithelium-derived factor in polycystic ovary syndrome and normal women: a case control study. Reprod Biol Endocrinol 2013;11:77. DOI: https://doi.org/10.1186/1477-7827-11-77
Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010;2010:758656. DOI: https://doi.org/10.1155/2010/758656
Tal R, Seifer DB, Arici A. The emerging role of angiogenic factor dysregulation in the pathogenesis of polycystic ovarian syndrome. Semin Reprod Med 2015;33:195-297. DOI: https://doi.org/10.1055/s-0035-1552582
Scholz A, Plate KH, Reiss Y. Angiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci 2015;1347:45-51. DOI: https://doi.org/10.1111/nyas.12726
Hayashi K-G, Acosta TJ, Tetsuka M, et al. Involvement of angiopoietin-tie system in bovine follicular development and atresia: messenger RNA expression in theca interna and effect on steroid secretion. Biol Reprod 2003;69:2078-84. DOI: https://doi.org/10.1095/biolreprod.103.017152
Nishigaki A, Okada H, Tsuzuki T, et al. Angiopoietin 1 and angiopoietin 2 in follicular fluid of women undergoing a long protocol. Fertil Steril 2011;96:1378-83. DOI: https://doi.org/10.1016/j.fertnstert.2011.09.031
Abramovich D, Irusta G, Bas D, et al. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. Endocrinology 2012;153:3446-56. DOI: https://doi.org/10.1210/en.2012-1105
Liu Z, Liu C, Hao C, et al. Aberrant expression of angiopoietin-like proteins 1 and 2 in cumulus cells is potentially associated with impaired oocyte developmental competence in polycystic ovary syndrome. Gynecol Endocrinol 2016;32:557-61. DOI: https://doi.org/10.3109/09513590.2016.1138463
Tal R, Seifer DB, Grazi RV, Malter HE. Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation. Vascular Cell 2013;5:18. DOI: https://doi.org/10.1186/2045-824X-5-18
Esteve E, Ricart W, Fernández-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 2009;32:S362-7. DOI: https://doi.org/10.2337/dc09-S340
Panidis D, Tziomalos K, Koiou E, et al. The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study. Reprod Biol Endocrinol 2010;8:151. DOI: https://doi.org/10.1186/1477-7827-8-151
Gencer M, Gazi E, Hacıvelioğlu S, et al. The relationship between subclinical cardiovascular disease and lipocalin-2 levels in women with PCOS. Eur J Obstet Gynecol Reprod Biol 2014;181:99-103. DOI: https://doi.org/10.1016/j.ejogrb.2014.07.032
Cakal E, Ozkaya M, Engin-Ustun Y, Ustun Y. Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. J Endocrinol Invest 2011;34:97-100. DOI: https://doi.org/10.1007/BF03347037
Yan Q-W, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:2533-40. DOI: https://doi.org/10.2337/db07-0007
Kahal H, Aburima A, Ungvari T, et al. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord 2015;15:14. DOI: https://doi.org/10.1186/s12902-015-0005-6
Koiou E, Tziomalos K, Katsikis I, et al. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecol Endocrinol 2012;28:20-4. DOI: https://doi.org/10.3109/09513590.2011.588745
Guo H, Zhang Y, Brockman DA, et al. Lipocalin 2 deficiency alters estradiol production and estrogen receptor signaling in female mice. Endocrinology 2012;153:1183-93. DOI: https://doi.org/10.1210/en.2011-1642
Martínez-García MA, Montes-Nieto R, Fernandez-Duran E, et al. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013;98:E388-96. DOI: https://doi.org/10.1210/jc.2012-3414
Nantermet PV, Xu J, Yu Y, et al. Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem 2004;279:1310-22. DOI: https://doi.org/10.1074/jbc.M310206200
Hu L, Shen H, Wu Q, et al. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. Clin Exp Obstet Gynecol 2014;41:288-92. DOI: https://doi.org/10.12891/ceog16222014
Diamanti-Kandarakis E, Livadas S, Kandarakis SA, et al. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol 2008;158:525-31. DOI: https://doi.org/10.1530/EJE-07-0822
Yilmaz Ö, Temur M, Calan M, et al. The relationship between lipocalin-2 and free testosterone levels in polycystic ovary syndrome. Endokrynol Pol 2017;68:7-12. DOI: https://doi.org/10.5603/EP.2017.0002
Saleh FL, Starkman H, Furness A, et al. Polycystic ovary syndrome in adolescents. Obstet Gynecol Clin North Am 2024;51:679-93. DOI: https://doi.org/10.1016/j.ogc.2024.08.005
Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril 2012;97:7-12. DOI: https://doi.org/10.1016/j.fertnstert.2011.11.023
Burgert TS, Paprocki E. PCOS and common androgen abnormalities in adolescents. NASPAG Essentials of Pediatric & Adolescent Gynecology 2025:190-204. DOI: https://doi.org/10.1016/B978-0-443-10512-8.00028-X
Ibáñez L, de Zegher F. Adolescent PCOS: a postpubertal central obesity syndrome. Trends Mol Med 2023;29:354-63. DOI: https://doi.org/10.1016/j.molmed.2023.02.006
Ibáñez L, Oberfield SE, Witchel S, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017;88:371-95. DOI: https://doi.org/10.1159/000479371
Milek M, Moulla Y, Kern M, et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci 2022;23:2222. DOI: https://doi.org/10.3390/ijms23042222
White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 1992;267:9210-3. DOI: https://doi.org/10.1016/S0021-9258(19)50409-4
Hertle E, Van Greevenbroek M, Stehouwer C. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 2012;55:881-4. DOI: https://doi.org/10.1007/s00125-012-2462-z
Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015;149:R219-27. DOI: https://doi.org/10.1530/REP-14-0435
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012;33:981-1030. DOI: https://doi.org/10.1210/er.2011-1034
Peake P, O'Grady S, Pussell B, Charlesworth J. Detection and quantification of the control proteins of the alternative pathway of complement in 3T3‐L1 adipocytes. Eur J Clin Invest 1997;27:922-7. DOI: https://doi.org/10.1046/j.1365-2362.1997.2090759.x
Chedraui P, Pérez-López FR, Escobar GS, et al. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas 2014;79:86-90. DOI: https://doi.org/10.1016/j.maturitas.2014.06.008
Derosa G, Fogari E, D’Angelo A, et al. Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation 2013;36:914-20. DOI: https://doi.org/10.1007/s10753-013-9620-4
Sivakumar K, Bari MF, Adaikalakoteswari A, et al. Elevated fetal adipsin/acylation-stimulating protein (ASP) in obese pregnancy: novel placental secretion via Hofbauer cells. J Clin Endocrinol Metab 2013;98:4113-22. DOI: https://doi.org/10.1210/jc.2012-4293
Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. Human Reprod 2013;28:777-84. DOI: https://doi.org/10.1093/humrep/des463
Rudnicka E, Kunicki M, Suchta K, et al. Inflammatory markers in women with polycystic ovary syndrome. Biomed Res Int 2020;2020:4092470. DOI: https://doi.org/10.1155/2020/4092470
Rajendiran L, Nandeesha H, Chitra T. Reduced angiopoietin-2 as a predictive biomarker for clomiphene citrate resistance in polycystic ovary syndrome. J Human Reprod Sci 2021;14:144-8. DOI: https://doi.org/10.4103/jhrs.jhrs_179_20
Wang L, Qi H, Baker PN, et al. Altered circulating inflammatory cytokines are associated with anovulatory polycystic ovary syndrome (PCOS) women resistant to clomiphene citrate treatment. Med Sci Monit 2017;23:1083-9. DOI: https://doi.org/10.12659/MSM.901194
Escobar-Morreale HcF, Botella-Carretero JI, Villuendas G, et al. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrino Metab 2004;89:806-11. DOI: https://doi.org/10.1210/jc.2003-031365
Khan D, Ansar Ahmed S. The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol 2016;6:635. DOI: https://doi.org/10.3389/fimmu.2015.00635
Petríková J, Lazúrová I, Yehuda S. Polycystic ovary syndrome and autoimmunity. Eur J Intern Med 2010;21:369-71. DOI: https://doi.org/10.1016/j.ejim.2010.06.008
Qi X, Yun C, Sun L, et al. Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med 2019;25:1225-33. DOI: https://doi.org/10.1038/s41591-019-0509-0
Dalmas E, Donath MY. A role for interleukin-22 in the alleviation of metabolic syndrome. Nat Med 2014;20:1379-81. DOI: https://doi.org/10.1038/nm.3748
Qi X, Yun C, Liao B, et al. The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome. J Endocrinol 2020;245:281-9. DOI: https://doi.org/10.1530/JOE-19-0589
Gao Z, Wang G, Ma X, et al. Troxerutin attenuates insulin resistance via pancreatic IL-22/JAK1/STAT3 signaling activation in dihydrotestosterone-induced polycystic ovary syndrome rats. Am J Physiol Endocrinol Metab 2022;323:E405-17. DOI: https://doi.org/10.1152/ajpendo.00150.2022
Stener-Victorin E, Padmanabhan V, Walters KA, et al. Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome. Endocr Rev 2020;41:bnaa010. DOI: https://doi.org/10.1210/endrev/bnaa010
Corrie L, Gulati M, Singh SK, et al. Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome. Life Sciences 2021;280:119753. DOI: https://doi.org/10.1016/j.lfs.2021.119753
van Houten ELA, Kramer P, McLuskey A, et al. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 2012;153:2861-9. DOI: https://doi.org/10.1210/en.2011-1754
How to Cite
Exploring some pro-inflammatory cytokines and adipokines as novel biomarkers in polycystic ovary syndrome. (2025). Italian Journal of Medicine, 19(3). https://doi.org/10.4081/itjm.2025.2023
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.